Yüklüyor......
Relapse rates in patients with multiple sclerosis treated with fingolimod: subgroup analyses of pooled data from three phase 3 trials
BACKGROUND: Fingolimod is a once-daily, orally administered therapy for relapsing forms of MS. It has been shown to reduce relapse rates significantly in all phase II and phase III clinical trials when compared with placebo and intramuscular interferon β-1a (IFNβ-1a IM). METHODS: This study compared...
Kaydedildi:
| Yayımlandı: | Mult Scler Relat Disord |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4985567/ https://ncbi.nlm.nih.gov/pubmed/27456887 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2016.05.015 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|